In order to assess the effectiveness of sildenafil under routine conditions of use in primary care settings and to evaluate its impact on patient's life satisfaction and partner's satisfaction with treatment for erectile dysfunction (ED), an open, multicentre, observational, prospective study was designed in which 2816 patients were treated with sildenafil for at least 10 weeks. Effectiveness was assessed using the International Index of Erectile Dysfunction (IIEF), life satisfaction was measured with 'Life-satisfaction Check List' (LISAT 8), and EDITS was optionally used to assess the partner's satisfaction with ED therapy. Sildenafil was effective in 86.6% of patients. All dimensions of IIEF significantly increased with sildenafil, particularly erectile domain which overall sample mean score improved was 13.2 points (P < 0.001). The greatest increases in satisfaction with all aspects of life were seen in sex life and relationship with partner dimensions. The patients' partners, answered by a minority of partners, were highly satisfied with the treatment and its rapid action, therefore they were in favour of continuing with same. The adverse events occurring were similar to those seen in clinical research on sildenafil in the premarketing phase. No control group was included in this study.
Introduction
According to the United States National Institute of Health Consensus Panel, erectile dysfunction (ED) is defined as the inability to achieve and=or maintain an adequate erection for a satisfactory sexual activity. 1 It is mainly associated with organic causes related to the circulatory, neurological or urological systems, although it can also be associated with a combination of physical and=or psychological factors or with emotional reasons only. 2 ED is a condition which affects up to 30 million men in the United States according to the Massachusetts Male Ageing Study. 3 In Spain, the results of the epidemiological study on ED (EDEM study) established a prevalence of ED ranging from 12% when ED perceived by the patient as considered to 19% when the disorder is detected by the administration of a specific questionnaire such as the International Index of Erectile Dysfunction (IIED). This means that approximately 2 million men in Spain aged from 25 to 70 y have some degree of ED. 4 Traditionally, ED has been treated in the setting of specialised medical care, amongst other reasons, because the therapeutic alternatives available were invasive and difficult to apply and monitor in primary care. The oral drugs available, antidepressants or peripheral vasodilators, were not effective and did not include this indication, and active molecules, such as intracavernous injections of vasoactive substances or the application of vacuum devices, although effective, required a close followup of the patient, which made their monitoring by the primary care physician virtually impossible. 5, 6 Sildenafil is the most effective oral therapy for treatment of ED and it has been evaluated in worldwide studies in over 4000 men from 19 to 87 y with ED caused by a wide variety of diseases, and has been shown to be an effective drug for treating this male condition. 7, 8 These studies have mainly assessed the efficacy and safety of the drug under clinical research conditions, that is, in conventional clinical trials, very different from the routine conditions of drug use in primary care. Moreover, apart from the clinical efficacy of the drug, it is interesting to establish its effectiveness, that is, its efficacy under routine conditions of use where the patient is not subjected to the rigorous controls required by clinical trials. It is also essential to assess its effectiveness from the point of view of the patient with ED and that of his partner. To this end, selfassessment techniques have been shown to be the best way of assessing sexual function, 9, 10 and multidimensional scales are considered more valid and sensitive from the psychometric point of view than unidimensional scales to assess the results of treatment. 11 For this purpose, the IIED is a reliable measure of erectile function whose cross-cultural validity has been shown, and which has adequate sensitivity and specificity to detect changes related to the treatment in patients with ED. 12, 13 However, the impact of ED treatment is not restricted exclusively to the achievement of an erectile response, but will reasonably often be transferred to other areas of life of the ED patient. Thus, some studies show a significant correlation between ED and quality of life. ED appears to have a clearly negative influence on the perception of quality of life in men with this problem. 14 In fact, according to the NIH (National Institutes of Health) panel for the study of ED, this male problem can be associated with depression, loss of self-esteem, poor self-concept, fear and mental stress, all of which have a negative effect on sexual relations with partners, on family and friends. ED can also lead the patient to withdraw from sexual and social relationships, causing an impairment in his overall state of health. 1 Studies on satisfaction with different aspects of life provide us with information, under routine conditions of use of drugs, on the effects that an improved sexual function has on other aspects of life of ED patients, with which they are closely associated. Subjective indicators of quality of life related to a health problem are increasingly popular in medical sciences due to the recognition of the importance of patient satisfaction and of how a person feels about the effects of a given treatment. In this regard, Fugl-Meyer's 15, 16 Life Satisfaction Check List (LISAT 8) has been shown to be a good instrument for assessing the satisfaction of ED patients with different aspects of their life. Satisfaction of the partner with the treatment also provides further information on the effectiveness of the treatment, since ED, although a male problem, directly affects the partner. It seems therefore appropriate to study the degree of satisfaction of the partner with ED treatment. The Erectile Dysfunction Inventory Treatment Satisfaction (EDITS) inventory, in its partner version, 17 has proved to be a reliable instrument for discovering the partner's satisfaction with the treatment of this type of patient, and can be easily administered in primary care.
Thus, the objectives of this study were: (1) To assess the effectiveness of sidenafil under routine conditions of use in primary care patients with ED; (2) to measure the changes caused by sildenafil in the satisfaction of these patients with different aspects of life; and (3) to establish the partner's satisfaction with treatment for ED.
Materials and methods
This was an open, multicentre, no-control-group, observational, prospective study, in which the patients act as their own controls and receive treatment under routine conditions of use based on the criterion of the physician. The physicians participating were all primary care physicians practising in Primary Care Health Centres throughout Spain. The study was conducted from May 1999 to January 2000, and each participating centre was requested to collect the information required by the study protocol on the first five consecutive patients (or until total foreseen sample was completed) with ED who was considered to require treatment with sildenafil by the judgement of the physician.
Information should be collected on patients who met the following requirements, in addition to agreeing to participate in the study: (a) men aged over 18 y; (b) with diagnosed ED (defined as a persistent inability to achieve and=or maintain an adequate erection for satisfactory sexual activity for at least 6 months previously) whatever the cause; and (c) having a stable partner relationship, thus allowing for regular sexual activity. Patients in whom treatment with sildenafil was contraindicated according to the prescribing information of the drug were excluded, as were those in whom the use of sildenafil was not recommended, such as: (a) patients under concomitant treatment with drugs containing nitrates or nitric oxide donors; (b) patients with anatomical penile deformities; (c) patients in whom sexual activity was contraindicated owing to severe cardiovascular dysfunction, such as unstable angina or severe heart failure not controlled with drugs, hypotensive patients ( < 90=50 mmHg) or patients with a recent history of stroke or MI (myocardial infarction); (d) patients with a known history of retinitis pigmentosa; (e) patients under concomitant treatment with other therapies for ED; or (f) patients known to be allergic to sildenafil or to any of its components.
Patients were enrolled in the study regardless of the organic or psychogenic origin of ED, and only information regarding main comorbidity was collected. Sildenafil was administered on the patient's demand, approximately an hour before attempting sexual activity. The patients were initially treated with a maximum dose of 50 mg=day which, depending on the response to treatment noted by the ED in a primary care setting A Gil et al patient, could be increased to 100 mg or decreased to 25 mg. The patients should be followed-up for at least 10 weeks (minimum period of time for seeing the effectiveness of the study drug and its ability to change the patient's satisfaction with different aspects of life).
The effectiveness of sildenafil to treat ED was assessed by an overall efficacy question to patients (Do you think that the treatment you have received in the past weeks has improved your erections?) and by their answers to the IIEF questionnaire. This questionnaire is a simple (15 items), reliable, multidimensional, self-administered tool which has shown its linguistic and psychometric validity for examining erectile function in different languages, including Spanish. 12, 13, 18 The questionnaire explores five dimensions of the sexual sphere: erectile function, orgasmic function, sexual desire, satisfaction with intercourse and overall satisfaction with sexual activity.
Life satisfaction was measured using a version of the LISAT 8 check-list previously validated in Spanish (Spain). This self-administered check-list has eight dimensions of a single item, which is scored on a Likert type scale: 1 (very dissatisfied), 2 (dissatisfied), 3 (rather dissatisfied), 4 (rather satisfied), 5 (satisfied), 6 (very satisfied). The dimensions measure satisfaction with eight different aspects of the patient's life: life in general, sexual life, relationship with partner, family life, relationship with friends, leisure, professional and financial situation. Both the IIEF and the LISAT 8 were completed at baseline and after the treatment period with sildenafil.
Satisfaction with ED treatment was assessed in partners who agreed voluntarily to answer the partner version of the EDITS inventory, 17 containing five items validated in Spanish, in order to know the partner's satisfaction with ED treatment, given the dyadic nature of this disease, and also to see whether the partner's answers agreed with that of the patient.
Statistical methods
Descriptive statistics were made of the primary and secondary variables of this study to assess dispersion and central trend statistics and to evaluate the distribution of the assessed variables. Percentages are given for the sociodemographic categorical variables and the EDITS questionnaire. The sample included in this study is assessed overall and by groups based on the main concomitant condition associated to ED shown by the patient: hypertension, diabetes, dyslipemia, depression and prostatic disease. The between-group sociodemographic and lifestyle categorical variables based on co-morbidity are compared using Pearson's w 2 test, and the continuous variables by an analysis of variance (ANOVA). A Student's t-test for paired data or a Wilcoxon's test was used to compare the answer to the different dimensions of the IIEF questionnaire in order to assess the mean change in score at the end of treatment in the overall sample. A one factor ANOVA model or the Kruskal-Wallis test was used to assess the mean change in score in the questionnaire at the end of treatment, according to comorbidity. A Wilcoxon's test was used for overall assessment of the answer to the life satisfaction questionnaire LISAT 8 in each of the items, and the change from the baseline score to the score at the end of therapy was compared between groups using the Kruskal-Wallis test.
All the tests were two-sided and an error a < 0.05 was accepted as significant in all comparisons. The study is protected against type b errors with a 90% statistical power. The clinical significance of the changes in the items of the questionnaires owing to the effect of the treatment was estimated using the Jacobson and Guyat approach. 19, 20 Results A total of 701 primary care physicians from all over Spain have participated in this study, providing information on 2816 male patients with ED with different co-morbidities treated with sildenafil between May 1999 and January 2000. Enrolment was stopped once the predetermined sample size was obtained. Table 1 shows the sociodemographic characteristics of the patient sample included in the study at the onset of treatment, overall and by comorbidity. High blood pressure was the most common concomitant disease in the study sample (27.3%), followed by diabetes (23.4%) and prostatic disease (21.2%). Due to the fact that patients were followed in a primary care setting, only symptomatic diagnosis was isolated. The mean age of patients was greater in the groups with high blood pressure and prostatic disease, whereas patients with depression showed the lowest mean age (F ¼ 66.61, P < 0.001). The proportion of obese patients (body mass index (BMI) ! 30 kg=m 2 ) in the overall sample was 14.5%, similar in all the groups studied except in patients with depression, in whom the proportion was significantly lower than in all other groups (w 2 ¼ 11.3, P < 0.05). Patients with dyslipaemia showed the greatest percentage of smokers, followed by patients with depression, whereas prostatic patients showed the lowest percentage of smokers (w 2 ¼ 13.2, P < 0.05). However, the average number of cigarettes smoked a day was no different by group of concomitant disease. By contrast, the proportion of regular alcohol consumers was similar in all groups. The ED in a primary care setting A Gil et al mean time since the occurrence of ED in the overall sample was 3.5 AE 2.9 y, and was shorter in patients with depression and dyslipaemia, whereas prostatic patients showed the longest mean duration of ED (F ¼ 4.07, P < 0.01). Only 12.5% of the patients had received previous treatment for ED before starting treatment with sildenafil; 48.1% had used intracavernous injections, whereas 20.1% had treated this problem with psychotropic drugs. The remaining 31.8% had tried other methods.
At the end of the study, 86.6% of the patients stated that their erections had improved considerably with the treatment received. By groups of concomitant diseases, slight but significant differences were seen in the effectiveness of sildenafil (w 2 ¼ 11.4, P < 0.05): high blood pressure (86.6%), diabetes (86.2%), hypercholesterolaemia (87.9%), depression (84.2%) and prostatic disease (83.9%). The patients took a mean of 12.8 AE 8.9 sildenafil tablets during the follow-up period (94.9 AE 16.8 days), and the dose used most often was 50 mg, which was taken by 81.8% of the subjects included in the study sample.
IIEF
Improvement in the erectile response of most of the patients was shown by the increased scores given by them in the five dimensions of the IIEF questionnaire. Figure 1 shows the changes in each IIEF dimension at the end of the study in all patients and Table 2 shows the changes for each group according to the main concomitant disease, together with the magnitude of the effect. All dimensions significantly increased (P < 0.001) at the end of treatment with sildenafil, with the greatest changes occurring in the Erectile Function dimension, and the smallest in the Sexual Desire dimension. The score increase at the end of the study was seen in all the groups based on co-morbidity, no bigger changes being seen in any particular group. The magnitude of the effect was clinically significant in all the dimensions of the IIEF questionnaire, but the overall satisfaction, erectile function and satisfaction with intercourse dimensions showed the greatest effect -over 2.0 -whereas orgasmic function and sexual desire showed a smaller clinical relevance. , Obese (BMI ! 30). The values are given as mean (s.d.) and relative frequency %-*P < 0.05, **P < 0.01, ***P < 0.001 in case of between-group differences by co-morbidity. Figure 2 shows the results before and after treatment for each of the dimensions of the LISAT 8 check-list, and Table 3 the changes and the magnitude of the effect in the dimensions of satisfaction with the different aspects of life analysed (life in general, sex life, relationship with partner, family life, relationship with friends, leisure, occupational and financial situation) in the different groups based on co-morbidity and in the overall sample. Figure 3 shows the answers to the LISAT 8 check-list before and after treatment depending on co-morbidity. The dimensions of sex life and relationship with partner are given the lowest scores by patients with ED before beginning treatment with sildenafil, regardless of whether the sample is assessed overall or by main co-morbidity. Patients with depression also had the lowest scores in the other dimensions related to life satisfaction before treatment when compared to the other groups (P < 0.001), except for diabetics, who also showed a significantly lower score in the sex life dimension than other groups (P < 0.01), but similar to that of patients with depression.
In the overall sample, treatment with sildenafil caused statistically significant changes in all the dimensions of the check-list, particularly in dimensions referring to relationship with the partner and sex life, which showed the greatest change during treatment ( Figure 2 ) and reached at the end of the A magnitude of effect > 0.5 was considered clinically relevant (in bold). **P < 0.01 and ***P < 0.001 for the differences based on comorbidity in the mean change of each dimension (see text).
ED in a primary care setting A Gil et al study scores similar to other dimensions. These two dimensions and, to a lesser extent, the dimensions of life in general and family life, were the only ones in which the change in response showed a clinically relevant effect (Table 3) . By groups based on comorbidity, sildenafil treatment achieved statistically significant changes in all dimensions of the checklist, particularly in sex life and relationship with partner, which showed the greatest increase (P < 0.001, Table 3 ). The dimensions of sex life and relationship with the partner also showed a clinically significant change in all the subgroups assessed, with no between-group differences in the changes. Diabetic patients and patients with depression also showed clinically significant changes in the dimension of life in general. However, when changes in response in the LISAT 8 dimensions were analysed by groups, it was seen that sildenafil achieved a greater therapeutic effect in patients with depression, who had a greater increase in the response to all LISAT 8 dimensions (P < 0.001), except for the variables sex life, relationship with partner, and financial situation, in which the response to treatment with sildenafil was independent of the co-morbidity group and similar in all of them ( Figure 3 ). On the other hand, the LISAT 8 check-list showed statistically significant differences after sildenafil treatment in the dimensions of sex life (P < 0.001) and relationship with partner (P < 0.001) amongst the patients showing improved erection (responders) as compared to patients not showing this improvement (non-responders, Figure 4) , and clinical relevance was also reached in the sex life dimension (magnitude of effect of 0.59). Figure 5 ) on partner's satisfaction with the treatment was optional, and only the partners of patients who had treated their ED previously with some therapy other than sildenafil (intracavernous injections, psychotropic drugs, vacuum devices, etc.) were required to ED in a primary care setting A Gil et al answer the EDITS inventory at the baseline visit. As a result, the percentage of answers to the questionnaire varied considerably between the baseline visit, when it was answered by 90 partners (3.2%), and the final visit, when it was answered by 677 partners (24.1%). At the baseline visit, when asked about the treatment received for ED (prior to sildenafil), the partners of the patients stated they were satisfied or very satisfied with the therapy in 28.4% of the cases, and only 32.6% thought that the treatment acted rapidly. Moreover, only 35.2% said that they wanted their partner to continue with the treatment administered for ED.
EDITS

Completion of the EDITS inventory (
By contrast, on the final visit after treatment with sildenafil, the opinions of the partners were considerably more positive, as 92.1% of them stated that they were satisfied or very satisfied with treatment, and 93.4% were satisfied with its rapid action. There were 85.4% of the partners who said that treatment with sildenafil had considerably or completely met their expectations, making them feel more sexually desirable in 88.5% of the cases. Finally, 95.4% of the partners stated that they would like their partner to continue with sildenafil treatment for their ED. Table 4 lists the adverse events reported by patients during the study follow-up with an incidence greater than 1%. A total of 515 patients (19.5%) experienced some type of adverse event during treatment with sildenafil, and the adverse event caused treatment discontinuation in 29 (5.6%) of those patients. The adverse events seen did not differ either in type or frequency from those expected based on clinical research on sildenafil in the pre-marketing phase.
Safety
Discussion
Sildenafil therapy was effective and well tolerated for treatment of ED in the sample studied, regardless of the main co-morbidity associated with ED. Thus, our study confirms the results found by other authors on the efficacy and good tolerability of sildenafil for treating ED, regardless of the associated concomitant disease (hypertension, depression, prostatic disease, diabetes, hyper-cholesterol-aemia). 21 -30 However, this study has shown slightly higher percentages of patients experiencing an improvement in their erections than those found in other studies, mainly controlled clinical trials, in which the overall effectiveness stands at around 78%, as compared to the 86% seen in our study. This disagreement can be explained by the observational character of the study performed, as opposed to the controlled clinical trials, in which the followup of patients is stricter and less flexible. However, a recent study performed in the United Kingdom with characteristics similar to our own has shown a similar response in terms of sildenafil effectiveness in patients with ED treated in primary care, 31 it should be pointed out that the present study did not include a control group, therefore, it is difficult to Figure 5 Answers to the questionnaire on partner's satisfaction with ED treatment (EDITS), before and after treatment with sidenafil in the dimensions of continuation of treatment, rapid action and degree of satisfaction with treatment. The different groups of concomitant diseases have shown differences regarding the effective dose of sildenafil, with the standard 50 mg dose having a lower percentage of effectiveness in some concomitant diseases, such as diabetes, although these results are consistent with those found in other studies conducted in this type of patients. 26, 27 The analysis of the answers given to the IIEF questionnaire show, regardless of the concomitant disease, statistically significant increases in the dimensions of erectile function, orgasmic function, satisfaction with intercourse and overall satisfaction and, to a lesser degree, sexual desire.
Baseline scores of life satisfaction were similar in all the groups with concomitant diseases, except for patients with depression, who systematically showed the lowest scores in all dimensions. It should be pointed out that after sildenafil treatment, the dimensions of sex life and relationship with partner showed similar scores in patients with depression to those in the other groups. These similar results to those found in the studies of Fugl-Meyer et al 15 are consistent if we remember that depression has a direct impact on all areas of life of patients who experience it. We, also, should remember that in their study, these authors classified patients with ED according to its cause (psychogenic, organic or mixed), and not based on specific diseases such as in this study.
Probably one of the most interesting and innovative contributions of this study consisted in the overall study of the profiles of answers to the LISAT 8 check-list based on the group to which the patients belonged. In this regard, whereas before the onset of treatment there were no significant differences between groups, except for patients with depression, after taking sildenafil the group of patients with this disease experienced a significant qualitative change in their profile as regards the answers to the questionnaire. After treatment, for all the groups considered, except patients with depression, it was systematically shown that although scores in the LISAT 8 were significantly higher, satisfaction with family life and with relationships with friends continued to be the most highly rated aspects of the patients' lives (as occurred before treatment). However, for patients with diagnosed depression, after treatment with sildenafil, life with the partner became the aspect of their lives with which they were most satisfied. However, the dimensions of sex life and relationship with the partner are the ones showing the greatest positive change after sildenafil treatment in all the groups.
Although we know of no similar studies with which to compare these results, other studies provide possible indirect explanations. For example, we know that ED and depression are highly correlated, 3,32 -34 and that patients with both these conditions show a clear decrease in desire compared to other patients with ED. 10, 35 Obviously, with the design used in this study, we cannot know to what extent depression has contributed to the ED or viceversa. However, since sexuality is currently a central aspect for keeping and developing a person's selfconcept, 11 it is, in theory, possible that a loss of erectile function can trigger, or at least potentiate, depressive symptoms. Thus, insofar as treatment with sildenafil improved the ED problem, it would also have an indirect impact on depression, improving not only the patient's self-esteem and selfconcept, but also his desire (an aspect closely related to the above). Obviously, the aspect that is primarily affected by these improvements is the most intimate area of the patient's life -his relationship with his partner -followed by family life, relations with friends, and leisure, all of which are involved in general satisfaction with life. Increases in these questions were precisely the ones which proved to be significant in patients with depression when compared to the other groups considered in the study.
The answers to the LISAT 8 check-list in patients with ED had a predictive value, since they allowed significant differences to be detected in the dimensions of sex life and relationship with partners -the ones most closely associated with ED -among patients experiencing erectile improvement with sildenafil treatment and those not showing this improvement with treatment, thus allowing them to be used to classify patients as responders and nonresponders with a single administration of this questionnaire or, more simply, with the question on their level of satisfaction with sex life.
Another of the most interesting aspects of the results obtained is the fact that treatment with sildenafil and the resulting improvement in sexual function has a persistent influence on other aspects of life not related to sexual ability, such as, for example, occupational status or financial aspects. In principle, an improved sexual function should only have a direct impact on those aspects of life with which it is most related, such as sexual relations, relationship with partners and family life. However, some studies show that there are a wide variety of medical, psychological, and even lifestyle factors involved in the aetiology of ED. And that this condition has a negative impact on self-esteem, on interpersonal relations and, what is more, on the quality of life of the patients who suffer from it. 36 -38 Taking this into account, it may be expected that when patients with ED experience a substantial ED in a primary care setting A Gil et al improvement in their sexual function, their level of self-esteem increases, changing their self-concept and improving their self-confidence. Therefore, this improvement can have a direct impact on other aspects of their lives, which are in principle independent from the sexual aspect. 39, 40 Finally, this study has included with the measurement of the efficacy of ED treatment with sildenafil, the opinion of the partners of patients. It is interesting to see that there is a certain agreement between the favourable opinions given by both patients and their partners on sildenafil treatment. Moreover, these results are similar to those reported by other studies. 17, 41, 42 Neither should we forget that sexual relations are dyadic in nature and it is therefore essential to have the opinion of both patients and partners when assessing the efficacy of a treatment. Participation of the partner in this type of study can also help the patient to feel more at ease and secure when acknowledging his problem and consulting the doctor, and on the other hand, entails a greater involvement of the partner in the solution of same, so that the ED ceases to be an individual problem and is considered a problem of the couple.
In the light of the results of this study, we agree with other authors in stating that the role of the primary care physician in the management of ED can consist in identifying patients with this condition, mainly in the high risk population, including patients with hypertension, diabetes, heart disease, etc, in making the symptomatic diagnosis, and in participating in the first stage of therapy.
